Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Salmeterol/fluticasone propionate - Evofem Biosciences

Next Previous
Drug Profile

Salmeterol/fluticasone propionate - Evofem Biosciences

Alternative Names: Fluticasone propionate/salmeterol - Evofem Biosciences; LIPO-102; Salmeterol xinafoate/fluticasone propionate - Evofem Biosciences; Salmeterol xinafoate/fluticasone propionate - Lithera

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lithera
  • Developer Evofem Biosciences; Neothetics
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eye disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II Exophthalmos
  • Discontinued Subcutaneous fat disorders

Most Recent Events

  • 17 Jan 2018 Evofem Biosciences merged with Neothetics to form Evofem Biosciences
  • 31 Dec 2016 Neothetics has patent protection for Salmeterol/fluticasone propionate in USA and other countries
  • 31 Mar 2015 Phase II development is ongoing in Exophthalmos in Australia and New Zealand

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top